临床观察恩替卡韦序贯聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎的疗效被引量：6

导出

摘要目的:探讨恩替卡韦(ETV)序贯聚乙二醇干扰素α-2a治疗HBe Ag阳性慢性乙型肝炎的临床疗效。方法:HBe Ag阳性CHB患者经过ETV治疗24周后,分为对照组(ETV单药治疗)30例和观察组(在ETV基础上加用Peg-IFNα-2a联合治疗)32例,继续治疗24周。检测HBe Ag血清学转换率和HBs Ag转阴率。结果:两组患者年龄分布、性别比例、血清HBe Ag和HBs Ag、HBV DNA载量在基线水平比较差异均无统计学意义(P>0.05)。治疗48周后。联合组HBs Ag阴转率、HBe Ag血清转换率均高于单药组(P<0.05)。结论:恩替卡韦序贯聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者,可提高患者血清HBs Ag的阴转率和HBe Ag血清学转换率。

作者徐敏

机构地区太原市第三人民医院

出处《山西职工医学院学报》 CAS 2016年第1期36-38,共3页 Journal of Shanxi Medical College for Continuing Education

关键词慢性肝炎聚乙二醇干扰素Α-2A 恩替卡韦

分类号 R453 [医药卫生—治疗学]

引文网络
相关文献

参考文献4

1郭斯敏,王晖,周惠娟,蔡伟,庄焱,赵钢德,郭清,杨菁,谢青.接受恩替卡韦治疗的e抗原阳性慢性乙型肝炎患者短程加用聚乙二醇干扰素-α-2a的抗病毒疗效和影响因素[J].中华传染病杂志,2015,33(1):14-19. 被引量：25
2张鸿飞,陈新月,谢尧,贺永文.聚乙二醇干扰素α-2a治疗核苷(酸)类似物经治者初探[J].传染病信息,2012,25(6):339-342. 被引量：6
3Chan HL,Wong VW,Tse AM, et al. Serum Hepatitis B Surface Anti- gen Quantitation can Reflect Hepatitis B Vires in the Liver and Predict Treatment Response [ J ]. Clin Gastroenterol Hepatol, 2007,5 ( 12 ) : 1462-1468.
4万谟彬,翁心华.干扰素治疗慢性乙型肝炎专家建议（2010年更新）[J].中华传染病杂志,2010(4):193-200. 被引量：106

二级参考文献18

1慢性乙型肝炎防治指南[J].中华传染病杂志,2005,23(6):421-431. 被引量：822
2Iloeje UH,Yang HI,Su J,陆伟（摘译）,张占卿（审校）.根据循环乙型肝炎病毒载量预测肝硬化的危险性[J].世界感染杂志,2006,6(4):396-396. 被引量：211
3European Association for the Study of the Liver.EASL clinical practice guidelines; management of chronic hepatitis B.J Hepatol,2009,50:227-242.
4Lok AS,McMahon BJ.Chronic hepatitis B:update 2009.Hepatology,2009,50:661-662.
5Cooksley WG,Piratvisuth T,Lee SD,et al.Peginterferon alpha-2a (40 kDa):an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.J Viral Hepat,2003,10:298-305.
6Lau GK,Piratvisuth T,Luo KX,et al.Peginterferon Alfa-2a,lamivudine,and the combination for HBeAg-positive chronic hepatitis B.N Engl J Med,2005,352:2682-2695.
7Marcellin P,Lau GK,Bonino F,et al.Peginterferon alfa-2a alone,lamivudine alone,and the two in combination in patients with HBeAg-negative chronic hepatitis B.N Engl J Med,2004,351:1206-1217.
8Janssen HL,van Zonneveld M,Senturk H,et al.Pegylated interferon alfa-2b alone or in combination with lamivudinefor HBeAg-positive chronic hepatitis B:a randomised trial.Lancet,2005,365:123-129.
9Lau GKK,Piratvisuth T,Luo KX,et al.Durability of response and occurrence of late response to peginterferon alpha-2a (40KD)[PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B.J Hepatology,2006,44(Suppl 2),S23-24.
10Marcellin P,Bonino F,Lau GK,et al.Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.Gastroenterology,2009,136:2169-2179.el-e4.